596 related articles for article (PubMed ID: 28057177)
1. [Not Available].
Fabre E; Pécuchet N; Cadranel J
Bull Cancer; 2016 Nov; 103 Suppl 1():S138-S143. PubMed ID: 28057177
[TBL] [Abstract][Full Text] [Related]
2. Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer.
Rossi E; Sgambato A; De Chiara G; Casaluce F; Losanno T; Sacco PC; Santabarbara G; Gridelli C
Expert Rev Clin Pharmacol; 2016; 9(3):419-28. PubMed ID: 26681547
[TBL] [Abstract][Full Text] [Related]
3. Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches.
Remon J; Pardo N; Martinez-Martí A; Cedrés S; Navarro A; Martinez de Castro AM; Felip E
Lung Cancer; 2017 Apr; 106():70-75. PubMed ID: 28285697
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy in Lung Cancer.
Du L; Herbst RS; Morgensztern D
Hematol Oncol Clin North Am; 2017 Feb; 31(1):131-141. PubMed ID: 27912829
[TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Herzberg B; Campo MJ; Gainor JF
Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
[TBL] [Abstract][Full Text] [Related]
6. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer.
Garon EB
Semin Oncol; 2015 Oct; 42 Suppl 2():S11-8. PubMed ID: 26477470
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges.
Giroux Leprieur E; Dumenil C; Julie C; Giraud V; Dumoulin J; Labrune S; Chinet T
Eur J Cancer; 2017 Jun; 78():16-23. PubMed ID: 28407528
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data.
Aguiar PN; De Mello RA; Hall P; Tadokoro H; Lima Lopes G
Immunotherapy; 2017 May; 9(6):499-506. PubMed ID: 28472902
[TBL] [Abstract][Full Text] [Related]
9. Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer.
Califano R; Kerr K; Morgan RD; Lo Russo G; Garassino M; Morgillo F; Rossi A
Curr Oncol Rep; 2016 Sep; 18(9):59. PubMed ID: 27484062
[TBL] [Abstract][Full Text] [Related]
10. The clinical utility of PD-L1 testing in selecting non-small cell lung cancer patients for PD1/PD-L1-directed therapy.
Villaruz LC; Socinski MA
Clin Pharmacol Ther; 2016 Sep; 100(3):212-4. PubMed ID: 27090296
[TBL] [Abstract][Full Text] [Related]
11. [Non-Small Cell Lung Cancer - from Immunobiology to Immunotherapy].
Bílek O; Bohovicová L; Demlová R; Poprach A; Lakomý R; Zdražilová-Dubská L
Klin Onkol; 2016; 29 Suppl 4(Suppl 4):78-87. PubMed ID: 27846725
[TBL] [Abstract][Full Text] [Related]
12. [Prolonged response with paclitaxel after immunotherapy by pembrolizumab in lung cancer].
Zapata E; Mennecier B; Leduc C; Chatron E; Quoix E
Rev Pneumol Clin; 2016 Oct; 72(5):300-304. PubMed ID: 27561974
[TBL] [Abstract][Full Text] [Related]
13. Targeting PD-L1 for non-small-cell lung cancer.
Feld E; Horn L
Immunotherapy; 2016 Jun; 8(6):747-58. PubMed ID: 27197542
[TBL] [Abstract][Full Text] [Related]
14. PD-1 Blockers.
Wolchok JD
Cell; 2015 Aug; 162(5):937. PubMed ID: 26317459
[TBL] [Abstract][Full Text] [Related]
15. Programmed death 1 immune checkpoint inhibitors.
Trivedi MS; Hoffner B; Winkelmann JL; Abbott ME; Hamid O; Carvajal RD
Clin Adv Hematol Oncol; 2015 Dec; 13(12):858-68. PubMed ID: 27058852
[TBL] [Abstract][Full Text] [Related]
16. [Immune checkpoint inhibitors (antibodies to PD1 and PD-L1), a new therapeutic weapon against non-small cell bronchial carcinoma].
Berghmans T; Grigoriu B; Sculier JP; Meert AP
Rev Mal Respir; 2018 Feb; 35(2):197-205. PubMed ID: 29395567
[TBL] [Abstract][Full Text] [Related]
17. The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderly.
Sgambato A; Casaluce F; Gridelli C
Expert Opin Biol Ther; 2017 May; 17(5):565-571. PubMed ID: 28276698
[TBL] [Abstract][Full Text] [Related]
18. Advances in the Treatment of Non-small Cell Lung Cancer: Focus on Nivolumab, Pembrolizumab, and Atezolizumab.
Leventakos K; Mansfield AS
BioDrugs; 2016 Oct; 30(5):397-405. PubMed ID: 27411930
[TBL] [Abstract][Full Text] [Related]
19. PD-1 Pathway Inhibitors: Immuno-Oncology Agents for Restoring Antitumor Immune Responses.
Medina PJ; Adams VR
Pharmacotherapy; 2016 Mar; 36(3):317-34. PubMed ID: 26822752
[TBL] [Abstract][Full Text] [Related]
20. [Immunotherapy in non-small cell lung cancer: inhibition of PD1/PDL1 pathway].
Guilleminault L; Carmier D; Heuzé-Vourc'h N; Diot P; Pichon E
Rev Pneumol Clin; 2015 Feb; 71(1):44-56. PubMed ID: 25687821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]